3,4-dihydroxyphenylethyl alcohol fenofibric acid ester and its preparation method and application
A technology of dihydroxyphenylethanol and fenofibrate ester, which is applied in the field of 3,4-dihydroxyphenylethanol fenofibrate ester and its preparation, can solve the problem of decreased glucose transport capacity of fat cells, insulin secretion disorder, Reduced insulin sensitivity and other problems, to achieve the effect of reducing triglyceride levels and total cholesterol levels, improving oxidative stress, and significantly reducing blood sugar activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0033] The present invention provides a new compound 3,4-dihydroxyphenethyl fenofibrate (HT-Fen) and a preparation method thereof. The present invention also provides that the compound is used in the preparation of the compound for the treatment of diabetes and hyperlipidemia. disease use.
[0034] The invention discloses a new compound 3,4-dihydroxyphenethyl fenofibrate (I), chemical name is 2-methyl-2-[4-(4-chlorobenzoyl)phenoxy ] Propionate-2-(3,4-dihydroxyphenyl)ethyl ester, referred to as 3,4-dihydroxyphenylethanol fenofibric ester (hydroxytyrosol fenofibric ester, HT-Fen).
[0035]
[0036]The hypoglycemic effect of HT-Fen of the present invention is achieved by the hypoglycemic effect of HT-Fen on the streptozotocin (STZ)-induced diabetes mouse model; the antioxidant effect of HT-Fen is achieved by reducing the streptozotocin (STZ) ( The lipid peroxidation product MDA of STZ)-induced diabetes mouse model was achieved; the lipid-lowering effect of HT-Fen was achieved...
Embodiment 1
[0044] Example 1: Preparation of HT-Fen
[0045] 3,4-Dihydroxyphenethyl alcohol (1.00g, 6.50mmol) and potassium carbonate (3.60g, 26.09mmol) were dissolved in acetone (25mL), benzyl bromide (1.40ml, 14.95mmol) was added, and the reaction was heated under reflux for 24h, After completion of the reaction, suction filtration and concentration. Column chromatography separation (developing solvent: petroleum ether and ethyl acetate) gave 1.46 g of 3,4-dibenzyloxyphenethyl alcohol as a pale yellow solid with a yield of 67.12%.
[0046] 3,4-Dibenzyloxyphenethyl alcohol (1.00g, 3.26mmol), fenofibric acid (1.56g, 4.89mmol) and DMAP (0.08g, 0.65mmol) were added to DMF (20mL), stirred for 5min and then added EDC·HCl (0.94g, 4.89mmol), stirred at room temperature, detected by thin layer plate, the reaction was completed, and the reactant was added with 5% NaHCO 3 The solution and saturated brine were washed twice in turn, and anhydrous Na 2 SO 4 Dry and concentrate to obtain 2.13 g of...
Embodiment 2
[0049] Example 2: Hypoglycemic effect and antioxidant effect of HT-Fen
[0050] Preparation of 0.1mmol / L pH4.5 citrate buffer:
[0051] Preparation of solution A (0.1 mol / L citric acid aqueous solution): 2.10 g of citric acid was added to distilled water to make 100 ml. Preparation of liquid B (0.1 mol / L trisodium citrate aqueous solution): add 2.94 g of trisodium citrate to 100 ml of distilled water. The 0.1 mol / L citric acid aqueous solution and the 0.1 mol / L trisodium citrate aqueous solution are mixed in a volume ratio of 1:1.44 to prepare a 0.1 mmol / L pH4.5 citric acid buffer.
[0052] STZ solution preparation: dissolve in 0.1mmol / L pH 4.5 citric acid buffer to prepare a 20mg / ml solution, ice bath, avoid light, and complete the injection within half an hour.
[0053] Establishment of diabetic mouse model: Mice were adaptively fed for 3 days, fasted for 12 hours, and injected intraperitoneally with STZ (using 0.1mol / L, pH4.5 citrate buffer, 200mg / kg) for 72 hours, fastin...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


